Washington Trust Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

Washington Trust Bank’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-11	Closed	–	–	692
2016 Q4	$0	Sell	11 -24	-69%	-$1K	﹤0.01%	1019
2016 Q3	$2K	Buy	+35	New	+$2.47K	﹤0.01%	696
2016 Q2	–	Sell	-100	Closed	-$6K	–	813
2016 Q1	$6K	Hold	100	–	–	﹤0.01%	616
2015 Q4	$9K	Hold	100	–	–	﹤0.01%	607
2015 Q3	$8K	Hold	100	–	–	﹤0.01%	635
2015 Q2	$12K	Hold	100	–	–	﹤0.01%	643
2015 Q1	$10K	Buy	100 +25	+33%	+$2.53K	﹤0.01%	673
2014 Q4	$7K	Hold	75	–	–	﹤0.01%	752
2014 Q3	$6K	Hold	75	–	–	﹤0.01%	721
2014 Q2	$5K	Hold	75	–	–	﹤0.01%	790
2014 Q1	$5K	Buy	+75	New	+$5.81K	﹤0.01%	740

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Washington Trust Bank's ALNY Position: Q1 2017 in Review

Washington Trust Bank sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2017, closing a stake of 11 shares.

Washington Trust Bank first reported a position in ALNY in Q1 2014 and held it in 11 quarters. The position peaked at $12K in Q2 2015. 199 funds tracked by Wall St. Rank hold ALNY as of Q1 2017.

Washington Trust Bank reported no remaining Alnylam Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Washington Trust Bank sold 11 Alnylam Pharmaceuticals shares in Q1 2017.
Washington Trust Bank first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 11 quarters.
Washington Trust Bank's Alnylam Pharmaceuticals position peaked at $12K in Q2 2015.
199 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2017.

Based on Washington Trust Bank's 13F filing for Q1 2017, filed 18 Apr 2017.